An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Surovatamig (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms ASSURO
- Sponsors AstraZeneca
Most Recent Events
- 08 Oct 2025 New trial record